# Xos, Inc.: financial statements, quarterly

XOS · Nasdaq · CIK 1819493 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xos.md) · [Financials](/companies/xos/financials.md) · [Filings](/companies/xos/filings.md) · [Insiders](/companies/xos/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xos/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [16.7](/filings/0001819493-24-000194.md) | [18.4 d](/filings/0001819493-25-000043.md) | [12.6](/filings/0001819493-24-000101.md) | [15.5](/filings/0001819493-25-000128.md) | [15.8](/filings/0001819493-25-000169.md) | [11.5 d](/filings/0001819493-26-000012.md) | [5.9](/filings/0001819493-26-000044.md) | [18.4](/filings/0001819493-26-000054.md) | [16.5](/filings/0001819493-25-000169.md) | [5.2 d](/filings/0001819493-26-000012.md) | [11.2](/filings/0001819493-26-000044.md) | [4.7](/filings/0001819493-26-000054.md) |
| Cost of revenue | $m | [14.7](/filings/0001819493-24-000194.md) | [17.0 d](/filings/0001819493-25-000043.md) | [10.4](/filings/0001819493-25-000081.md) | [13.5](/filings/0001819493-25-000128.md) | [12.9](/filings/0001819493-25-000169.md) | [15.2 d](/filings/0001819493-26-000012.md) | [4.7](/filings/0001819493-26-000044.md) | [16.8](/filings/0001819493-26-000054.md) | [14.0](/filings/0001819493-25-000169.md) | [7.9 d](/filings/0001819493-26-000012.md) | [6.9](/filings/0001819493-26-000044.md) | [4.2](/filings/0001819493-26-000054.md) |
| Gross profit | $m | [2.0](/filings/0001819493-24-000194.md) | [1.3 d](/filings/0001819493-25-000043.md) | [2.8](/filings/0001819493-25-000081.md) | [2.0](/filings/0001819493-25-000128.md) | [2.9](/filings/0001819493-25-000169.md) | [(3.7) d](/filings/0001819493-26-000012.md) | [1.2](/filings/0001819493-26-000044.md) | [1.6](/filings/0001819493-26-000054.md) | [2.5](/filings/0001819493-25-000169.md) | [(2.6) d](/filings/0001819493-26-000012.md) | [4.3](/filings/0001819493-26-000044.md) | [0.6](/filings/0001819493-26-000054.md) |
| Research and development | $m | [4.5](/filings/0001819493-24-000194.md) | [4.1 d](/filings/0001819493-25-000043.md) | [3.1](/filings/0001819493-25-000081.md) | [3.0](/filings/0001819493-25-000128.md) | [2.6](/filings/0001819493-25-000169.md) | [1.9 d](/filings/0001819493-26-000012.md) | [1.9](/filings/0001819493-26-000044.md) | [2.1](/filings/0001819493-26-000054.md) | [2.1](/filings/0001819493-25-000169.md) | [1.9 d](/filings/0001819493-26-000012.md) | [2.0](/filings/0001819493-26-000044.md) | [1.9](/filings/0001819493-26-000054.md) |
| Operating income | $m | [(12.6)](/filings/0001819493-24-000194.md) | [(11.8) d](/filings/0001819493-25-000043.md) | [(10.2)](/filings/0001819493-25-000081.md) | [(11.4)](/filings/0001819493-25-000128.md) | [(9.7)](/filings/0001819493-25-000169.md) | [(14.6) d](/filings/0001819493-26-000012.md) | [(9.3)](/filings/0001819493-26-000044.md) | [(7.1)](/filings/0001819493-26-000054.md) | [(7.0)](/filings/0001819493-25-000169.md) | [(9.7) d](/filings/0001819493-26-000012.md) | [(4.7)](/filings/0001819493-26-000044.md) | [(7.9)](/filings/0001819493-26-000054.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001819493-24-000194.md) | [0.0 d](/filings/0001819493-25-000043.md) | [0.0](/filings/0001819493-25-000081.md) | [0.0](/filings/0001819493-25-000128.md) | [0.0](/filings/0001819493-25-000169.md) | [0.0 d](/filings/0001819493-26-000012.md) | [0.0](/filings/0001819493-26-000044.md) | [0.0](/filings/0001819493-26-000054.md) | [(0.0)](/filings/0001819493-25-000169.md) | [0.0 d](/filings/0001819493-26-000012.md) | [0.0](/filings/0001819493-26-000044.md) | [0.0](/filings/0001819493-26-000054.md) |
| Net income | $m | [(14.1)](/filings/0001819493-24-000194.md) | [(13.8) d](/filings/0001819493-25-000043.md) | [(11.0)](/filings/0001819493-25-000081.md) | [(9.7)](/filings/0001819493-25-000128.md) | [(10.5)](/filings/0001819493-25-000169.md) | [(19.0) d](/filings/0001819493-26-000012.md) | [(10.2)](/filings/0001819493-26-000054.md) | [(7.5)](/filings/0001819493-26-000054.md) | [2.1](/filings/0001819493-25-000169.md) | [(9.8) d](/filings/0001819493-26-000012.md) | [(4.9)](/filings/0001819493-26-000054.md) | [(6.9)](/filings/0001819493-26-000054.md) |
| Diluted EPS | $ per share | [(2.40)](/filings/0001819493-24-000194.md) | not reported | [(1.80)](/filings/0001819493-25-000081.md) | [(1.23)](/filings/0001819493-25-000128.md) | [(1.32)](/filings/0001819493-25-000169.md) | not reported | [(1.26)](/filings/0001819493-26-000044.md) | [(0.90)](/filings/0001819493-26-000054.md) | [0.22](/filings/0001819493-25-000169.md) | not reported | [(0.43)](/filings/0001819493-26-000044.md) | [(0.55)](/filings/0001819493-26-000054.md) |
| Basic EPS | $ per share | [(2.40)](/filings/0001819493-24-000194.md) | not reported | [(1.80)](/filings/0001819493-25-000081.md) | [(1.23)](/filings/0001819493-25-000128.md) | [(1.32)](/filings/0001819493-25-000169.md) | not reported | [(1.26)](/filings/0001819493-26-000044.md) | [(0.90)](/filings/0001819493-26-000054.md) | [0.22](/filings/0001819493-25-000169.md) | not reported | [(0.43)](/filings/0001819493-26-000044.md) | [(0.55)](/filings/0001819493-26-000054.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [22.6](/filings/0001819493-24-000194.md) | [11.6](/filings/0001819493-25-000043.md) | [46.2](/filings/0001819493-25-000081.md) | [19.7](/filings/0001819493-25-000128.md) | [8.4](/filings/0001819493-25-000169.md) | [11.0](/filings/0001819493-26-000012.md) | [4.8](/filings/0001819493-25-000081.md) | [8.8](/filings/0001819493-25-000128.md) | [14.1](/filings/0001819493-25-000169.md) | [14.0](/filings/0001819493-26-000054.md) | [9.8](/filings/0001819493-26-000044.md) | [13.2](/filings/0001819493-26-000054.md) |
| Current assets | $m | [91.5](/filings/0001819493-23-000252.md) | [71.7](/filings/0001819493-25-000043.md) | [113](/filings/0001819493-24-000101.md) | [100](/filings/0001819493-24-000156.md) | [97.6](/filings/0001819493-24-000194.md) | [82.3](/filings/0001819493-26-000012.md) | [73.1](/filings/0001819493-25-000081.md) | [66.6](/filings/0001819493-25-000128.md) | [62.5](/filings/0001819493-25-000169.md) | [49.9](/filings/0001819493-26-000054.md) | [45.3](/filings/0001819493-26-000044.md) | [45.0](/filings/0001819493-26-000054.md) |
| Total assets | $m | [114](/filings/0001819493-23-000252.md) | [93.7](/filings/0001819493-25-000043.md) | [135](/filings/0001819493-24-000101.md) | [123](/filings/0001819493-24-000156.md) | [121](/filings/0001819493-24-000194.md) | [98.3](/filings/0001819493-26-000012.md) | [87.7](/filings/0001819493-25-000081.md) | [80.3](/filings/0001819493-25-000128.md) | [73.8](/filings/0001819493-25-000169.md) | [60.4](/filings/0001819493-26-000054.md) | [54.4](/filings/0001819493-26-000044.md) | [54.4](/filings/0001819493-26-000054.md) |
| Current liabilities | $m | [27.2](/filings/0001819493-23-000252.md) | [19.6](/filings/0001819493-25-000043.md) | [22.3](/filings/0001819493-24-000101.md) | [20.1](/filings/0001819493-24-000156.md) | [50.2](/filings/0001819493-24-000194.md) | [46.7](/filings/0001819493-26-000012.md) | [45.4](/filings/0001819493-25-000081.md) | [30.1](/filings/0001819493-25-000128.md) | [26.0](/filings/0001819493-25-000169.md) | [23.0](/filings/0001819493-26-000054.md) | [23.9](/filings/0001819493-26-000044.md) | [22.5](/filings/0001819493-26-000054.md) |
| Total liabilities | $m | [56.6](/filings/0001819493-23-000252.md) | [48.5](/filings/0001819493-25-000043.md) | [67.2](/filings/0001819493-24-000101.md) | [64.2](/filings/0001819493-24-000156.md) | [69.7](/filings/0001819493-24-000194.md) | [64.7](/filings/0001819493-26-000012.md) | [62.9](/filings/0001819493-25-000081.md) | [62.0](/filings/0001819493-25-000128.md) | [42.8](/filings/0001819493-25-000169.md) | [36.4](/filings/0001819493-26-000054.md) | [34.6](/filings/0001819493-26-000044.md) | [31.6](/filings/0001819493-26-000054.md) |
| Short-term borrowings | $m | [1.7](/filings/0001819493-23-000252.md) | [1.0](/filings/0001819493-25-000043.md) | [0.7](/filings/0001819493-24-000101.md) | [1.3](/filings/0001819493-24-000156.md) | [2.1](/filings/0001819493-24-000194.md) | [1.3](/filings/0001819493-26-000012.md) | [0.5](/filings/0001819493-25-000081.md) | [1.1](/filings/0001819493-25-000128.md) | [1.6](/filings/0001819493-25-000169.md) | [1.0](/filings/0001819493-26-000054.md) | [0.3](/filings/0001819493-26-000044.md) | [0.7](/filings/0001819493-26-000054.md) |
| Shareholders' equity | $m | [57.6](/filings/0001819493-24-000194.md) | [45.2](/filings/0001819493-26-000012.md) | [67.8](/filings/0001819493-25-000169.md) | [59.2](/filings/0001819493-25-000169.md) | [50.8](/filings/0001819493-25-000169.md) | [34.1](/filings/0001819493-26-000054.md) | [25.3](/filings/0001819493-26-000054.md) | [18.9](/filings/0001819493-26-000054.md) | [31.1](/filings/0001819493-25-000169.md) | [24.0](/filings/0001819493-26-000054.md) | [20.5](/filings/0001819493-26-000054.md) | [22.9](/filings/0001819493-26-000054.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.6) d](/filings/0001819493-24-000194.md) | [(0.6) d](/filings/0001819493-25-000043.md) | [(14.6)](/filings/0001819493-25-000081.md) | [(26.0) d](/filings/0001819493-25-000128.md) | [(11.5) d](/filings/0001819493-25-000169.md) | [3.3 d](/filings/0001819493-26-000012.md) | [(4.8)](/filings/0001819493-26-000044.md) | [4.6 d](/filings/0001819493-26-000054.md) | [3.1 d](/filings/0001819493-25-000169.md) | [2.4 d](/filings/0001819493-26-000044.md) | [(1.6)](/filings/0001819493-26-000044.md) | [(2.7) d](/filings/0001819493-26-000054.md) |
| Capital expenditure | $m | [(0.2) d](/filings/0001819493-24-000194.md) | [0.2 d](/filings/0001819493-25-000043.md) | [0.0](/filings/0001819493-25-000081.md) | [0.1 d](/filings/0001819493-25-000128.md) | [0.1 d](/filings/0001819493-25-000169.md) | [0.0 d](/filings/0001819493-26-000012.md) | [0.0](/filings/0001819493-26-000044.md) | [0.0 d](/filings/0001819493-26-000054.md) | [0.0 d](/filings/0001819493-25-000169.md) | [0.0 d](/filings/0001819493-26-000012.md) | [0.0](/filings/0001819493-26-000044.md) | [0.0 d](/filings/0001819493-26-000054.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [174](/filings/0001819493-23-000252.md) | [5.6](/filings/0001819493-24-000101.md) | [5.7](/filings/0001819493-24-000156.md) | [5.9](/filings/0001819493-24-000194.md) | [6.1](/filings/0001819493-25-000081.md) | [7.9](/filings/0001819493-25-000128.md) | [8.0](/filings/0001819493-25-000169.md) | [8.1](/filings/0001819493-26-000044.md) | [8.3](/filings/0001819493-26-000054.md) | [9.8](/filings/0001819493-25-000169.md) | [11.6](/filings/0001819493-26-000044.md) | [12.6](/filings/0001819493-26-000054.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 14,217,852 at 2026-08-07, from the cover of the [10-Q filed 2026-08-13](/filings/0001819493-26-000054.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.